Background Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing ( N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
【저자키워드】 COVID-19, SARS-CoV-2, Breast cancer, outcome, survival, 【초록키워드】 Corticosteroid, Treatment, Hospitalized, intensive care, severe COVID-19, hospital, Comorbidities, Diagnosis, Comorbidity, risk, Symptom, cough, hypertension, RNA, ground-glass opacity, Characteristics, COVID-19 infection, Fever, Patient, death, France, age, Viral RNA, anti-cancer treatment, COVID-19 symptoms, Admission, clinical feature, association, radiation therapy, Analysis, COVID-19 mortality, deaths, COVID-19 patient, lung lesions, lung CT scan, Factor, higher risk, Paris, Abnormalities, Univariate analysis, positive, radiological features, breast cancer patients, Curie, ICH, breast cancer patient, common, Result, defined, radiologic, died, reported, treated, cured, was done, COVID-19 complication, diagnosed with COVID-19, transferred, with COVID-19, 【제목키워드】 hospital, Cohort, Paris, Curie,